Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Gray Sheet

Executive Summary

Arrow recall benefits Utah Medical: Salt Lake City firm's neonatal sales rise 28% in Q1 as former customers of Arrow International's NeoPICC 1.9 Fr peripheral central catheter, voluntarily recalled in December, purchase Utah Medical's products as replacements, CEO Kevin Cornwell states in April 21 call (1"The Gray Sheet" Jan. 24, 2005, p. 26). In the first quarter, Utah Medical revenue totaled $6.7 mil., up 1% versus the prior-year period. The firm's obstetrics product sales slipped 6%, hampering growth....FDA v. Utah Medical: Exec notes a Department of Justice complaint seeking to halt Utah Medical sales after an FDA inspection cited persistent QSR lapses dating to 2001 is slated for a June 20 pre-trial hearing in Salt Lake City federal court (2"The Gray Sheet" Aug. 23, 2004, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel